Abstracts Archive - Page 2308 of 2425 - ACR Meeting Abstracts

Abstract Number: 1701 • 2012 ACR/ARHP Annual Meeting
Validation of the New ASAS Criteria for Classification of Early Spondyloarthritis in the Esperanza Cohort
Eva Tomero¹, Loreto Carmona², Juan Mulero³, Eugenio De Miguel⁴, Milena Gobbo⁵, Carmen Martínez⁶, Miguel A. Descalzo⁶, Pedro Zarco⁷, Eduardo Collantes-Estevez⁸ and Esperanza Group⁹, ¹Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²Health Sciences School, Universidad Camilo José Cela, Villanueva de la Cañada, Spain, ³Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Spain, ⁴Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁵Research Unit, Spanish Society of Rheumatology., Madrid, Spain, ⁶Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁷Unit Rheumatology, Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain, ⁸Depatamento de Medicina, IMIBIC-Reina Sofia Hospital, Cordoba 14012, Spain, ⁹Madrid
Background/Purpose: To validate the new axial and peripheral ASAS criteria in patients with early spondyloarthritis (SpA) and the full spectrum of clinical manifestations under clinical…
Abstract Number: 1702 • 2012 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Blocking Agents Inhibit the Progression of Preclinical Atherosclerosis in Patients with Ankylosing Spondylitis
Alper M. van Sijl¹, Izhar C. van Eijk², Mike J.L. Peters³, Erik H. Serne³, Yvo M. Smulders⁴ and Mike T. Nurmohamed¹, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Internal medicine, VU University Medical Center, Amsterdam, Netherlands, ⁴Internal Medicine, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) is associated with an increased cardiovascular (CV) risk that might be due to the chronic underlying inflammatory process. It is still…
Abstract Number: 1703 • 2012 ACR/ARHP Annual Meeting
Relationship Between Tobacco Smoking and Radiographic Spinal Progression in Axial Spondyloarthritis: The Role of Inflammatory Activity
Denis Poddubnyy¹, Hildrun Haibel², Joachim Listing³, Elisabeth Märker-Hermann⁴, Henning Zeidler⁵, Jürgen Braun⁶, Martin Rudwaleit⁷ and Joachim Sieper⁸, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Dr. Horst Schmidt Kliniken, Wiesbaden, Germany, ⁵Medizinische Hochschule, Hannover, Germany, ⁶PsAID taskforce, EULAR, Zurich, Switzerland, ⁷Endokrinologikum Berlin, Berlin, Germany, ⁸Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: Cigarette smoking is associated with functional impairment [1, 2] and radiographic severity of ankylosing spondylitis (AS) [3, 4]. Moreover, smoking status at baseline was…
Abstract Number: 1704 • 2012 ACR/ARHP Annual Meeting
New Threshold Values for Spinal Mobility Measures Based On a Large Nationally Representative Sample of U.S. Adults Ages 20-69 Years
Shervin Assassi¹, Michael H. Weisman², Zhongxue Chen³, Mohammad Rahbar³ and John D. Reveille⁴, ¹Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Univ of Texas Health Science Center at Houston, Houston, TX, ⁴Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Spinal mobility measures are widely utilized for diagnosis and assessment of disease severity in patients with Ankylosing Spondylitis. The previously proposed threshold values for…
Abstract Number: 1705 • 2012 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol On Inflammation of Spine and Sacroiliac Joints in Patients with Axial Spondyloarthritis: 12 Week Magnetic Resonance Imaging results of a Phase 3 Double Blind Randomized Placebo-Controlled Study
Désirée van der Heijde¹, Walter P. Maksymowych², Robert B. M. Landewé³, Christian Stach⁴, Bengt Hoepken⁴, Andreas Fichtner⁴, Danuta Kielar⁵ and Jürgen Braun⁶, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ⁴UCB Pharma, Monheim am Rheim, Germany, ⁵UCB Pharma, Brussels, Belgium, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) and is defined by the ASAS criteria.1 It is characterized by bone…
Abstract Number: 1706 • 2012 ACR/ARHP Annual Meeting
Predictive Atherosclerotic Risk Factors At Inception in a Multicentre, Multinational Cohort
Murray B. Urowitz¹, Dominique Ibanez¹, D. D. Gladman² and SLICC³, ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada
Background/Purpose: Patients with systemic lupus erythematosus (SLE) develop premature atherosclerosis (AS). This study examines predictive factors at inception for atherosclerotic vascular events (AVE) over…
Abstract Number: 1707 • 2012 ACR/ARHP Annual Meeting
The Association of Serum Biomarkers and Metabolic Syndrome with Subclinical Atherosclerosis in Systemic Lupus Erythematosus: A Controlled Analysis in Patients with No Clinical Disease Activity
Semra Ertan-Demir¹, Ahmet Yasar Cizgici², Gaye Erten³, Bahar Artim-Esen⁴, Yasemin Sahinkaya⁴, Özlem Pehlivan⁴, Nilüfer Alpay-Kanitez⁴, Kadri Atay¹, Huseyin Oflaz², Gunnur Deniz³ and Murat Inanc⁴, ¹Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Cardiology Department, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³Department of Immunology, Istanbul University, Institute of Experimental Medicine (DETAE), Istanbul, Turkey, ⁴Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of developing atherosclerotic cardiovascular disease (CVD). In addition to traditional CVD risk factors or…
Abstract Number: 1708 • 2012 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Cardiovascular Risk Equation
Michelle Petri¹ and Laurence S. Magder², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Accelerated atherosclerosis remains the major late cause of death in SLE. Yet, the "traditional" cardiovascular risk equations (Framingham, Reynolds, SCORE) consistently underestimate the risk. …
Abstract Number: 1709 • 2012 ACR/ARHP Annual Meeting
Biomarkers of Atherosclerosis Are Associated with Progression of Non-Cardiovascular Damage in Patients with SLE
Sarah J. Kim¹, Jennifer M. Grossman², Brian Skaggs³, Elaine Lourenco³, Lori Sahakian⁴, John FitzGerald⁵, Nagesh Ragavendra⁶, Christina Charles-Schoeman⁷, Alan H. Gorn⁸, Bevra H. Hahn⁸ and Maureen A. McMahon⁹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Div of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³Medicine/Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴Division of Rheumatology, Department of Medicine,, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁶Radiology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁷University of California, Los Angeles, CA, ⁸Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁹Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Studies have shown that even after taking traditional cardiac risk factors into account, SLE patients have up to 50-fold higher risk of developing atherosclerotic…
Abstract Number: 1710 • 2012 ACR/ARHP Annual Meeting
Increase in Vitamin D Improves Disease Activity and Systolic Blood Pressure in Systemic Lupus Erythematosus
Kayode J. Bello¹, Hong Fang², Laurence S. Magder³ and Michelle Petri², ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Vitamin D deficiency has also been associated with different chronic conditions including cardiovascular diseases such as coronary artery disease, cardiac failure and hypertension. In…
Abstract Number: 1711 • 2012 ACR/ARHP Annual Meeting
Association of Vascular Calcification and Perivascular Adipose Tissue of the Descending Aorta with Cardiovascular Events in SLE
Kelly J. Shields¹, Emma Barinas-Mitchell², Amy H. Kao³, Susan Manzi⁴ and Kim Sutton-Tyrrell², ¹Medicine, Lupus Center of Excellence / Allegheny Health Network, Pittsburgh, PA, ²Epidemiology, University of Pittsburgh, Pittsburgh, PA, ³Lupus Center of Excellence, Allegheny Singer Research Institute, Pittsburgh, PA, ⁴Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Women with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease (CVD). We have shown that clinically CVD-free women with SLE have…
Abstract Number: 1712 • 2012 ACR/ARHP Annual Meeting
The Submaximal Heart and Pulmonary Evaluation: A Novel Noninvasive Test to Identify Pulmonary Hypertension in Patients with Systemic Sclerosis
Elana J. Bernstein¹, Jessica K. Gordon², Robert F. Spiera², Lisa A. Mandl² and Evelyn M. Horn³, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Cardiology, New York Presbyterian Hospital/Weill Cornell Medical College, New York, NY
Background/Purpose: Pulmonary hypertension (PH), defined as a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg on right heart catheterization (RHC), is a leading cause of…
Abstract Number: 1713 • 2012 ACR/ARHP Annual Meeting
Developing an Index for Disease Activity and Therapeutic Response in Connective Tissue Disease Related Interstitial Lung Disease: Results From A Delphi Exercise: Delivering A Consensus On Domains
Lesley Ann Saketkoo¹, Dörte Huscher², Dinesh Khanna³, Paul F. Dellaripa⁴, Kevin Flaherty⁵, Chester V. Oddis⁶, Kristine Phillips⁷, Athol U. Wells⁸, Christopher P. Denton⁹, Oliver Distler¹⁰, Otylia M. Kowal-Bielecka¹¹, Romy Christmann¹², Nora Sandorfi¹³, David Pittrow¹⁴, Vibeke Strand¹⁵, James R. Seibold¹⁶, Kevin K. Brown¹⁷ and Eric L. Matteson¹⁸, ¹LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ³Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Department of Critical Care and Pulmonary Medicine, University of Michigan, Ann Arbor, MI, ⁶Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheumatology, University of Michigan, Ann Arbor, MI, ⁸Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, ⁹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ¹⁰Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹¹Department of Rheumatology and Internal Medicine, Medical University in Bialystok, Bialystok, Poland, ¹²Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Division of Rheumatology, Thomas Jefferson Univ Med Coll, Philadelphia, PA, ¹⁴Institute of Clinical Pharmacology - University of Dresden, Dresden, Germany, ¹⁵Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ¹⁶Scleroderma Research Consultants LLC, Avon, CT, ¹⁷Autoimmune Lung Center, National Jewish Hospital, Denver, CO, ¹⁸Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Lack of reliable and valid measures of disease activity and clinical response in patients with connective tissue disease (CTD)-related interstitial lung disease (ILD) makes…
Abstract Number: 1714 • 2012 ACR/ARHP Annual Meeting
Gender Differences in Systemic Sclerosis: Relationship to Disease Specific Clinical Manifestations and Estradiol Levels
Christine Peoples¹, Mary Lucas², Zengbiao Qi², Thomas A. Medsger Jr.³ and Carol A. Feghali-Bostwick⁴, ¹Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ³Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by inflammation, autoantibody production, and increased production of extracellular matrix (ECM), resulting in fibrosis. We…
Abstract Number: 1715 • 2012 ACR/ARHP Annual Meeting
Imatinib Mesylate (Gleevec™) in the Treatment of Diffuse Cutaneous Systemic Sclerosis: Results of a 24 Month Open Label, Extension Phase
Jessica K. Gordon¹, Morgana L. Davids², Kamini Doobay², Jamie N. Mersten¹, Cynthia Magro³, Horatio F. Wildman⁴, Stephen L. Lyman⁵, Mary K. Crow⁶ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medicine/Rheumatology, Hospital for Special Surgery, New York, NY, ³Dermatopathology, Weill-Cornell Medical Center, New York, NY, ⁴Dermatology, Weill-Cornell Medical Center, New York, NY, ⁵Research, Hospital for Special Surgery, New York, NY, ⁶Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Imatinib mesylate (IM) has been shown to decrease fibrosis in preclinical models and is a treatment of interest for Systemic Sclerosis (SSc). We have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].